Wayne has held numerous, senior positions in multi-national companies. Throughout his career, he has been responsible for building businesses throughout the world, as well as mergers and major restructures. From 2007 to 2013, he held senior positions at Merck Serono. In his most recent position as President of Europe, Canada and Australia, he managed over $3 billion in sales with an operational budget of $500 million. Wayne also held the position of Global Head of Cardio Metabolic Care and General Medicine, with revenue responsibility of $1.5 billion, and was responsible for all aspects of company strategy, including manufacturing strategies, commercial operations and budgets. Between 2010 and 2012, he was Head of Emerging Markets including Russia, China, India and Brazil, and was a member of the Executive Board. As President during 2007 until 2010 in Japan, Wayne created Merck Serono Japan and successfully managed all company divisions, launching several major products. Between 1994 and 2005, he was employed by Roche Pharmaceuticals. As Marketing Director in Shanghai, China, he launched eight products during this time, including cardiovascular products. Wayne is an Australian national and has resided overseas since 1999, having lived in China, Singapore, Korea, Japan, Switzerland and the US. He now lives in Switzerland, where he is CEO and co-founder of a software company that provides solutions to the global pharmaceutical industry. Wayne is also a Non-Executive Director of Cepheid (NASDAQ: CHPD), a molecular diagnostics company based in California. Wayne holds an MBA from the University of Southern Queensland, and a degree in business studies from the Queensland University of Technology. He has also studied business courses at North Western University (Kellog School of Management) in Chicago, IMD Business School in Switzerland, INSEAD in France and Hong Kong University of Technology.
Chief Executive Officer
Chief Operating Officer
Julian Chick is an experienced corporate executive with 15 years’ experience in senior management. His roles include Chief Executive Officer and Head of Business Development, as well as running early and late stage Research & Development projects. In the past six years, Dr Chick has raised hundreds of million dollars for R&D projects as well as being involved in product launches and partnerships, M&A and licensing transactions. He has five years’ investment adviser experience and has also held a role as an analyst reviewing healthcare and biotechnology investment opportunities for private equity investors and venture capitalists. Julian has a PhD in Muscle Physiology.
Chief Financial Officer
Mark is a highly credentialed CFO and business partner with a strong track record of delivering growth and significant operational improvements across a wide variety of industries (medtech, FMCG, technology and consulting) and geographies (New Zealand, Pacific Islands, Indonesia, Sri Lanka, Hong Kong, Taiwan, Japan, South Korea, Vietnam, United States and Europe).
His strong capabilities and experience in financial and business performance management are complimented by extensive corporate finance, M&A, financial control, investment decision making, risk management, strategy development and IT skills gained at leading global organisations including Cochlear, Aristocrat Leisure, Coca-Cola Amatil and Goodman Fielder.
A collaborative leader and influencer skilled in stakeholder management and effectively partnering businesses and their management teams to deliver sustainable results. Above all, Mark is known for providing rigorous and insightful advice and commercial recommendations, and respected for his preparedness to challenge the status quo.
Mark’s qualification include a bachelor of commerce, CPA designation and an MBA majoring in international business.
Chief Technical Operations Officer
Scott has 20 years of manufacturing experience within the medical device industry and over 15 years with biologic tissue manufacturing in positions including Director of Manufacturing, Plant Manager, and Vice President of Operations. Scott lead the Synovis manufacturing team in improving operating margin from 56% to 78% and being awarded the Manufacturer of the Year in 2011 from Manufacturers Alliance for LEAN improvements, customer service, and employee engagement. Scott has a Mechanical Engineering degree from the University of Minnesota and a Masters in Manufacturing Systems from the University of St. Thomas.
Chief Human Resources and Technology Officer
Ben Jensen has been with Admedus since 2014 and is an experienced Human Resources professional with a background in manufacturing, supply chain, resources and engineering industries. His experience in business planning and change management within HR teams in North and South America, Europe, India and Asia Pacific has equipped him with broad strategic capabilities.
Over 20 years he has gained his credentials in industrial relations, occupational health and safety, organisational and leadership development programs, performance management, engagement and retention strategies, remuneration and benefits planning. Ben has worked with Queensland University of Technology on both undergraduate and post graduate programs including the Project Management Academy. He has accreditations in psychometric and ability assessment tools and specialised in global recruitment, talent management and employer branding initiatives.
Ben has a Business Management degree, a Masters of Employment Law and is a member of the Australian Institution of Company Directors.
Vice President Field Force Optimisation
20 plus years in clinical and senior leadership roles. Clinical practice experience in pulmonary, critical care and surgical services.
At Synovis Life Technologies, Eileen was Product Manager for market development in cardiothoracic, bariatric and general surgery, With the acquisition of Synovis by Baxter, Eileen managed professional education and training.
A Bachelor’s degree in management – Cardinal Stritch University, Master’s certificate in Health Care Administration – University of St. Thomas. Eileen also served on the board of directors for the Surgical Review Corporation and the Virginia Society of Bariatric Surgery and chaired the corporate council for the ASMBS.
Vice President - North America
Natalee practiced in the areas of Intensive Care and Surgery.
Nursing degree – Union University, Bachelor’s degree in Business Administration (Summa Cum Laude) and a Masters’ in Administration from Central Michigan University.
Natalee has a strong background in surgical devices, biologicals and capital equipment. A long and successful track record at Baxter saw Natalee hold Director level positions in National Accounts, Health Systems, Reimbursement Initiatives and Training.
Vice President - Emerging Markets
Danny Zanardo has over 20 years experience in the Australian Health Care sector via positions with multinational pharmaceutical companies, biopharmaceutical start-up, and medical device companies. He has gained formal qualifications via a degree in applied science and has built upon this with post graduate business studies, and is currently working towards completing his MBA.
During his career Danny has developed strong networks and an intimate understanding of medical device and pharmaceutical commercial and clinical environments. He has a successful track record of leading sales, marketing and clinical teams in commercial projects, with new and existing medical technology, that have resulted in significant revenue growth. Danny has worked with Rousell Uclaf, Hoffman La Roche, and Actelion. He joined Allied Medical as a Regional Sales Manager in 2004 and became National Sales Manager in 2005.
Vice President - Europe
Michael is responsible for all commercial activity in Europe. A dual Australian/Swiss national based in Zurich, Michael studied pharmacy at Sydney University and is an experienced and versatile global executive with strategic and operational healthcare marketing and sales experience across many diverse therapeutic areas. Michael has broad experience in sales and global product management at Roche, Novo Nordisk and CSL.